You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The platform retained high sensitivity after exposure to plasma for more than one month, opening up a range of potential diagnostic applications, the researchers said.
The research team said that its diagnostic biomarkers may help clinicians differentiate a fatal disease for preterm infants from other confounding conditions.
Newly discovered biomarkers of preterm birth risk — D-lactic acid and TIMP-1 — may lead to a simple ELISA test at the point of care, its developers said.
The study reflects the importance of including multiple biomarkers for diagnostic and treatment decisions associated with pneumonia, IVD industry experts said.
The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
The decision, which enables Medicare reimbursement, is effective for tests administered on or after Dec. 1.
BioDirection is collaborating with CENTER-TBI, an EU initiative that aims to advance the care of patients with traumatic brain injury.
The researchers said the test performed well in distinguishing patients with or without complications and proved itself better than frequently used clinical variables.
Erada Technology Alliance said the Global Health Innovative Technology Fund grant facilitates production, testing, and validation trials for the rapid test for malaria.
The firm said it anticipates launching the platform in Europe next year and completing its first round of external financing in the first quarter of 2020.